Author Interviews, Cannabis, JAMA, Mental Health Research / 22.02.2026
Kaiser Permanente Study Finds Higher Risk of Psychiatric Disorders in Teens Who Reported Cannabis Use
Editor’ note: Cannabis and THCA/HEMP CBD products should have an active ingredient list on the container and have a Certificate of Analysis (COA).
Discuss your use of THC, Cannabis or CBD products with your health care provider. Dosing of Cannabis products is variable, especially since they are not FDA regulated. Cannabis/CBD may interfere with other medications and should not be used in individuals with certain health conditions, including liver issues. CBD skin care products can be absorbed through the skin and have similar effects. Do not use Cannabis products including edibles, drinks and CBD if you are pregnant, nursing or may become pregnant. Do not use cannabis products if driving or operating difficult or dangerous machinery. Children should not be exposed to cannabis or CBD products.
MedicalResearch.com Interview with:
[caption id="attachment_72552" align="alignleft" width="200"]
Dr. Young-Wolff[/caption]
Kelly Young-Wolff, PhD, MPH
Licensed clinical psychologist and Research Scientist
Kaiser Permanente Northern California Division of Research
Associate Professor, Psychiatry
School of Medicine
UCSF Weill Institute for Neurosciences
MedicalResearch.com: What is the background for this study?
Response: Cannabis is widely used by adolescents, and it’s often first used during the same developmental window when many psychiatric disorders begin to emerge. At the same time, cannabis has become more accessible and more socially accepted. While prior studies have linked adolescent cannabis use to mental health symptoms, fewer large studies have examined whether it’s associated with later clinically diagnosed psychiatric disorders. We wanted to address that gap.
Dr. Young-Wolff[/caption]
Kelly Young-Wolff, PhD, MPH
Licensed clinical psychologist and Research Scientist
Kaiser Permanente Northern California Division of Research
Associate Professor, Psychiatry
School of Medicine
UCSF Weill Institute for Neurosciences
MedicalResearch.com: What is the background for this study?
Response: Cannabis is widely used by adolescents, and it’s often first used during the same developmental window when many psychiatric disorders begin to emerge. At the same time, cannabis has become more accessible and more socially accepted. While prior studies have linked adolescent cannabis use to mental health symptoms, fewer large studies have examined whether it’s associated with later clinically diagnosed psychiatric disorders. We wanted to address that gap.
Scott Kaplan PhD
Assistant Professor of Economics
United States Naval Academy
Annapolis, MD 21402
MedicalResearch.com: What is the background for this study?
Response: Sugar-sweetened beverages (colloquially known as SSBs), which include sodas, fruit drinks, sports drinks, energy drinks, and sweetened coffee drinks, are the leading source of added sugars in the American diet, according to the CDC. They are associated with serious negative health outcomes, including type 2 diabetes, obesity, heart disease, kidney disease,
Joanna Jiang, PhD
Agency for Healthcare Research and Quality
Rockville, Maryland
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Over the last decade we have seen two trends occurring to rural hospitals – closures and mergers. A hospital in financial distress could likely face closure. But if the hospital affiliates with a multihospital system, it may have access to resources from the system that help shelter the hospital from closure.
That is exactly what we found in this study. System affiliation was associated with a lower risk of closure for financially distressed hospitals. However, among hospitals that were financially stable, system affiliation was associated with a higher risk of closure. This is somewhat puzzling and needs further study to better understand the reason for closure.
Dr. Eberly[/caption]
Lauren A. Eberly, MD, MPH
Clinical Fellow, Cardiovascular Medicine
Perelman School of Medicine
Cardiovascular Division, Perelman School of Medicine
Center for Cardiovascular Outcomes, Quality, and Evaluative Research,
Cardiovascular Center for Health Equity and Social Justice,
Leonard Davis Institute of Health Economics
University of Pennsylvania, Philadelphia
MedicalResearch.com: What is the background for this study?
Response: Racial inequities are pervasive in our country, and cardiovascular therapeutics with proven benefit have been shown to be underutilized among Black and Latinx patients.
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a recommended treatment option for glycemic control in patients with diabetes, have recently emerged as a cardioprotective therapy as multiple large randomized clinical trials have shown they prevent cardiovascular events among patients with Type 2 Diabetes (T2D), particularly patients with established atherosclerotic cardiovascular disease (ASCVD). Given this, they are now recommended therapy for patients with diabetes and established or high risk of ASCVD.
Given the known inequitable utilization of other therapies, along with the known higher burden of diabetes and cardiovascular disease among Black patients, the aim of this study was to evaluate the uptake of GLP-1 RA as well as for inequities in utilization.